Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) EVP Ryan Savitz sold 3,044 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $90.03, for a total transaction of $274,051.32. Following the completion of the transaction, the executive vice president owned 29,276 shares in the company, valued at approximately $2,635,718.28. This trade represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Ryan Savitz also recently made the following trade(s):
- On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total transaction of $1,605,085.44.
- On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02.
- On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total transaction of $230,848.54.
Dianthus Therapeutics Price Performance
Shares of NASDAQ:DNTH traded up $3.18 during trading on Thursday, reaching $92.48. The stock had a trading volume of 921,016 shares, compared to its average volume of 931,449. The stock has a market capitalization of $5.21 billion, a PE ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88. The business’s 50-day moving average price is $89.05 and its 200 day moving average price is $86.15.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. Analysts forecast that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.
Wall Street Analyst Weigh In
DNTH has been the topic of several research analyst reports. Citigroup began coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 target price on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday, November 5th. JPMorgan Chase & Co. assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Finally, Truist Financial increased their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $128.77.
Read Our Latest Research Report on DNTH
Institutional Trading of Dianthus Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. EFG International AG bought a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $49,000. GAMMA Investing LLC lifted its holdings in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after buying an additional 254 shares in the last quarter. Fifth Third Bancorp boosted its position in Dianthus Therapeutics by 23.6% in the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock valued at $60,000 after buying an additional 129 shares during the last quarter. Global Retirement Partners LLC bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $93,000. Finally, Nisa Investment Advisors LLC boosted its position in Dianthus Therapeutics by 75.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock valued at $93,000 after buying an additional 453 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.
Featured Articles
- Five stocks we like better than Dianthus Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
